The Anthropic Long-Term Benefit Trust has appointed Vas Narasimhan to Anthropic's Board of Directors. Narasimhan, a physician-scientist and the Chief Executive Officer of Novartis, brings experience in overseeing the development and approval of numerous novel medicines within a highly regulated industry. According to Anthropic co-founder and president Daniela Amodei, his background in safely scaling powerful technology aligns with the company's daily focus. The Anthropic Long-Term Benefit Trust is an independent body designed to maintain a responsible balance between financial success and Anthropic's public benefit mission. Neil "Buddy" Shah, chair of the Trust, noted that Narasimhan's career stewarding breakthrough science provides a valuable perspective for developing consequential technology. With this appointment, Trust-appointed directors now hold a majority on the board, joining members such as Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. Narasimhan expressed enthusiasm for joining the board, highlighting AI's transformative potential in healthcare, from deepening the understanding of disease biology to designing better medicines. In addition to his role at Novartis, Narasimhan has worked on global health programs, serves on various boards including Harvard Medical School and the University of Chicago, and is a member of the US National Academy of Medicine. In other company updates, Anthropic is granting employee-like access to frontier AI model evaluator METR, strengthening election safeguards for US midterms, and opening a new office in Singapore alongside a memorandum of understanding with the country's government.
Anthropic’s Long-Term Benefit Trust appoints Vas Narasimhan to Board of Directors
Anthropic's Long-Term Benefit Trust has appointed Novartis CEO and physician-scientist Vas Narasimhan to its Board of Directors. Narasimhan brings extensive experience in developing novel medicines and navigating heavily regulated industries. With his appointment, Trust-appointed directors now form a majority on Anthropic's board.
Why it matters
The appointment strengthens governance focused on responsible AI development by adding a leader with deep expertise in scaling highly regulated medical innovations. It also gives independent Trust-appointed directors a majority on Anthropic's board, reinforcing its dual commitment to financial success and public benefit.